Method of treatment using interferon-tau
AssigneePepgen Corporation
InventorsChih-Ping Liu, Lorelie Villarete
Life of this patent
Estimating the term…
Abstract
Methods of treating an autoimmune condition by administering IFNτ are described. IFNτ is administered orally at a dose sufficient to achieve obtain a desired clinical endpoint, such as a reduction in new contrast-enhanced brain lesions in multiple sclerosis patients.
Claims12
A method for treating an autoimmune condition in a human subject, comprising
- orally administering interferon-tau to the subject at a daily dosage of at least about 1×108 Units, and
- continuing to orally administer interferon-tau to the subject until a desired clinical endpoint is achieved.
The method of claim 16, wherein said second therapeutic agent is selected from the group consisting of anti-cancer agents and agents suitable for treatment of autoimmune disorders.
A method of treating slowing progression of multiple sclerosis in a subject, comprising
- orally administering interferon-tau to the subject at a daily dosage of at least about 1×108 Units, and
- continuing to orally administer interferon-tau to the subject until a reduction in new contrast-enhanced brain lesions is observed.
A method of reducing the risk of relapse in a subject suffering from multiple sclerosis, comprising
- orally administering interferon-tau to the subject at a daily dosage of at least about 1×108 Units, and
- continuing to orally administer interferon-tau to the subject until a reduction in new contrast-enhanced brain lesions is observed.
Dependencies are inferred from the claim text.